From leukapheresis to infusion: what actually happens while a patient waits for CAR-T
Conventional CAR-T therapy turns one patient’s T cells into one personalized drug batch through collection, genetic engineering, expansion, testing and release. Faster autologous, allogeneic and in-vivo approaches are trying to collapse that process from weeks toward days.